Show simple item record

dc.contributor.authorCruz Rodriguez, Nataly
dc.contributor.authorCombita, Alba L.
dc.contributor.authorEnciso, Leonardo J.
dc.contributor.authorQuijano, Sandra M.
dc.contributor.authorPinzon, Paula L.
dc.contributor.authorLozano, Olga C.
dc.contributor.authorCastillo, Juan S.
dc.contributor.authorLi, Li
dc.contributor.authorBareño, Jose
dc.contributor.authorCardozo, Claudia
dc.contributor.authorSolano, Julio
dc.contributor.authorHerrera Jauregui, Maria Victoria
dc.contributor.authorCudris, Jennifer
dc.contributor.authorZabaleta, Jovanny
dc.date.accessioned2022-06-13T16:06:01Z
dc.date.accessioned2023-05-11T19:34:57Z
dc.date.available2022-06-13T16:06:01Z
dc.date.available2023-05-11T19:34:57Z
dc.date.created2016-04-05
dc.identifierhttps://jeccr.biomedcentral.com/articles/10.1186/s13046-016-0333-zspa
dc.identifier.issn0392-9078 / 1756-9966 (Electrónico)spa
dc.identifier.urihttps://hdl.handle.net/20.500.12032/116707
dc.description.abstractBackground: B-Acute lymphoblastic leukemia (B-ALL) represents a hematologic malignancy with poor clinical outcome and low survival rates in adult patients. Remission rates in Hispanic population are almost 30 % lower and Overall Survival (OS) nearly two years inferior than those reported in other ethnic groups. Only 61 % of Colombian adult patients with ALL achieve complete remission (CR), median overall survival is 11.3 months and event-free survival (EFS) is 7.34 months. Identification of prognostic factors is crucial for the application of proper treatment strategies and subsequently for successful outcome. Our goal was to identify a gene expression signature that might correlate with response to therapy and evaluate the utility of these as prognostic tool in hispanic patients. Methods: We included 43 adult patients newly diagnosed with B-ALL. We used microarray analysis in order to identify genes that distinguish poor from good response to treatment using differential gene expression analysis. The expression profile was validated by real-time PCR (RT-PCT). Results: We identified 442 differentially expressed genes between responders and non-responders to induction treatment. Hierarchical analysis according to the expression of a 7-gene signature revealed 2 subsets of patients that differed in their clinical characteristics and outcome. Conclusions: Our study suggests that response to induction treatment and clinical outcome of Hispanic patients can be predicted from the onset of the disease and that gene expression profiles can be used to stratify patient risk adequately and accurately. The present study represents the first that shows the gene expression profiling of B-ALL Colombian adults and its relevance for stratification in the early course of disease.spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAcute lymphoblastic leukemiaspa
dc.subjectGene expression profilespa
dc.subjectComplete remissionspa
dc.subjectMinimal residual diseasespa
dc.titleHigh expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemiaspa


Files in this item

FilesSizeFormatView
68.pdf2.891Mbapplication/pdfView/Open

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/

© AUSJAL 2022

Asociación de Universidades Confiadas a la Compañía de Jesús en América Latina, AUSJAL
Av. Santa Teresa de Jesús Edif. Cerpe, Piso 2, Oficina AUSJAL Urb.
La Castellana, Chacao (1060) Caracas - Venezuela
Tel/Fax (+58-212)-266-13-41 /(+58-212)-266-85-62

Nuestras redes sociales

facebook Facebook

twitter Twitter

youtube Youtube

Asociaciones Jesuitas en el mundo
Ausjal en el mundo AJCU AUSJAL JESAM JCEP JCS JCAP